



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl



Semi-rigid tripeptide agonists of melanocortin receptors

Andrew R. Ruwe^a, Leonid Koikov^{b,*}, Zalfa Abdel-Malek^b, Carrie Haskell-Luevano^d, Marvin L. Dirain^d, Federico Portillo^d, Zhimin Xiang^d, Matt Wortman^c, James J. Knittel^{a,*}

^a University of Cincinnati, James L. Winkle College of Pharmacy, Cincinnati, OH 45267, USA

^b University of Cincinnati, College of Medicine, Department of Dermatology, Cincinnati, OH 45267, USA

^c University of Cincinnati, Genome Research Institute, Cincinnati, OH 45237, USA

^d University of Florida, College of Pharmacy, Gainesville, FL 32610, USA

ARTICLE INFO

Article history:

Received 7 May 2009

Revised 23 June 2009

Accepted 2 July 2009

Available online 9 July 2009

Keywords:

Melanocortin receptors

Melanocortin agonists

N-capping

Peptidomimetics

Conformational analysis

Molecular modeling

ABSTRACT

A series of 30 RCO-HfRW-NH₂ derivatives show preference for the mouse MC1R vs MC3-5Rs. *trans*-4-HOC₆H₄CH=CHCO-HfRW-NH₂ (**13**) [EC₅₀ (nM): MC1R 83, MC3R 20500, MC4R 18130 and MC5R 935; ratio 1:246:217:11] is 11 times more potent than the lead compound LK-394 Ph(CH₂)₃CO-HfRW-NH₂ (**2**) and only 11 times less potent than the native tridecapeptide α-MSH at mMC1R. Differences in conformations of **2** and **13** are discussed.

© 2009 Elsevier Ltd. All rights reserved.

Melanocortin receptors (MCRs) are found in different tissues, have a plethora of physiological functions¹ and are a target of intensive pharmacological research.² Five MCRs (MC1R–MC5R) have been cloned. From the very onset of research in this area, the role of melanocortins in skin pigmentation has been firmly established and shown to be the result of activation of the MC1R. α-, β- and γ-Melanocyte stimulating hormones (MSH), the natural agonists of MC1, MC3, MC4 and MC5Rs, sharing the common melanocortin core sequence His⁶-Phe⁷-Arg⁸-Trp⁹ (HfRW), and their synthetic analogs (NDP-MSH, MT-II) with a similar His⁶-D-Phe⁷-Arg⁸-Trp⁹ (HfRW) core are very potent but non-selective. Although many peptide and non-peptide ligands of MCRs have been reported, pharmacological differentiation of properties of MC1, MC3, MC4 and MC5Rs is still a major challenge.^{1,2}

α-MSH	Ac-Ser-Tyr-Ser-Met-Glu-His ⁶ -Phe ⁷ -Arg ⁸ -Trp ⁹ -Gly-Lys-Pro-Val-NH ₂
NDP-MSH	Ac-Ser-Tyr-Ser-Nle-Glu-His ⁶ -D-Phe ⁷ -Arg ⁸ -Trp ⁹ -Gly-Lys-Pro-Val-NH ₂
LK-184 (1)	Ph(CH ₂) ₃ CO-His ⁶ -D-Phe ⁷ -Arg ⁸ -Trp ⁹ -NH ₂
LK-394 (2)	Ph(CH ₂) ₃ CO-His ⁶ -D-Phe ⁷ -Arg ⁸ -NH ₂
Compounds 3–32	RCO-His ⁶ -D-Phe ⁷ -Arg ⁸ -NH ₂











* Corresponding authors. Present address: Western New England College, School of Pharmacy, Springfield, MA 01119 USA. Fax: + 413 796 2266 (J.J.K.); +1 513 558 5061 (L.K.).

E-mail addresses: lkoikov@hotmail.com (L. Koikov), jknittel@wnec.edu (J.J. Knittel).

Recently, we have described a superpotent hMC1R agonist LK-184 Ph(CH₂)₃CO-HfRW-NH₂ (**1**) with an EC₅₀ of 0.01 nM and ca. 500-fold selectivity for hMC1R compared to hMC3 and hMC4Rs.^{3a} Truncation of **1** to Ph(CH₂)₃CO-HfRW-NH₂ gave a full hMC1 agonist LK-394 (**2**) with an EC₅₀ of 5 nM and weak partial agonism at hMC3/4Rs.^{3b} We have also shown that tetrapeptide **1** was more potent than α-MSH in repairing DNA damage resulting from exposure to solar UV radiation, in addition to stimulating pigmentation that confers further photoprotection and prevents mutagenesis.^{4a} Such double-headed action can be used as an effective prevention strategy for the most fatal skin cancer—melanoma.^{4b} The goal of this work was to explore modifications of the N-terminal end-capping group on the HfRW-NH₂ core sequence in order to increase potency and/or selectivity at MC1R compared to the lead compound **2** and provide insight into the interaction of short peptides with MCRs.

Our previous studies on the tetrapeptides RCO-HfRW-NH₂ suggested that an aromatic π-binding site in the hMC1R conferred selectivity of the N-capped peptides for this receptor over other hMCRs.³ Thus, all tripeptides in this study contained an aromatic ring connected to the C=O group via C₂ (**3–10**, **12–16** and **18–25**), C₃ (**26–28**) or C₄ (**29–31**) spacer, a cyclic C₂ mimic (**11** and **17**) or directly (**32**) (Table 1). For mapping the putative π-binding site, cinnamic derivatives **3–9**, **12**, **13**, **15**, **16**, **18**, **20** and **23–25** provided a shorter and more rigid C₂ link compared to the freely rotating saturated C₃ chain in **2**, while the substituents in their phenyl rings provided an extended conjugated π system overlapping the

Table 1Agonist activity of N-capped tripeptides on mouse MC1, MC3, MC4, and MC5 receptors¹¹

#	RCO-His-D-Phe-Arg-NH ₂ R	EC ₅₀ (nM) ± SEM			
		mMC1R	mMC3R	mMC4R	mMC5R
1	Ph(CH ₂) ₃ CO-His-D-Phe-Arg-Trp-NH ₂ (LK-184)	1.60 ± 0.29	26.0 ± 4.0	0.54 ± 0.19	0.33 ± 0.14
2		940 ± 260	43,700 ± 1370	15,140 ± 8800	11,800 ± 5950
3		1200 ± 390	^a	52,950 ± 6580	30,220 ± 8200
4		1160 ± 570	28,050 ± 22,600	14,700 ± 5800	6860 ± 1200
5		1690 ± 465	^a	13,700 ± 4700	12,850 ± 1710
6		3660 ± 1170	^a	60,400 ± 19,500	18,400 ± 7600
7		660 ± 190	33,800 ± 13,300	4010 ± 240	6390 ± 1100
8		310 ± 70	30,300 ± 17,000	3700 ± 500	6780 ± 490
9		274 ± 68	^a	12,740 ± 4120	2770 ± 330
10		1120 ± 216	^a	^a	9600 ± 3940
11		1175 ± 330	7380 ± 1240	17,200 ± 2700	2280 ± 615

(continued on next page)

Table 1 (continued)






















#	RCO-His-D-Phe-Arg-NH ₂ R	EC ₅₀ (nM) ± SEM			
		mMC1R	mMC3R	mMC4R	mMC5R
12		1080 ± 300	58,900 ± 56,000	5200 ± 1700	6900 ± 1400
13		83.3 ± 13.7	20,500 ± 12,600	18,130 ± 3258	935 ± 310
14		1160 ± 88	a	a	10,540 ± 3200
15		420 ± 61	a	11,500 ± 4920	3410 ± 360
16		780 ± 230	a	a	6640 ± 1830
17		620 ± 26	a	a	4760 ± 1300
18		567 ± 253	a	23,600 ± 1780	6187 ± 1400
19		7280 ± 4400	a	25,500 ± 3400	23,000 ± 4700
20		1250 ± 130	a	23,500 ± 9900	17,600 ± 3090
21		1670 ± 437	a	a	18,050 ± 4510

Table 1 (continued)

#	RCO-His-D-Phe-Arg-NH ₂ R	EC ₅₀ (nM) ± SEM			
		mMC1R	mMC3R	mMC4R	mMC5R
22		3200 ± 670	^a	38,700 ± 6370	70,300 ± 11,350
23		2790 ± 650	^a	19,200 ± 4100	19,300 ± 1340
24		2060 ± 330	^a	42,800 ± 21600	8500 ± 1720
25		8200 ± 2150	^a	20,300 ± 6400	^a
26		990 ± 180	24,100 ± 4100	5020 ± 1980	3080 ± 210
27		1745 ± 685	^a	22,750 ± 5870	16,580 ± 2307
28		1230 ± 320	^a	12,400 ± 2240	10,500 ± 620
29		500 ± 195	16,800 ± 4530	4710 ± 1370	6830 ± 1060
30		780 ± 430	19,500 ± 2900	10,050 ± 1270	6230 ± 790


(continued on next page)

Table 1 (continued)

#	RCO-His-D-Phe-Arg-NH ₂ R	EC ₅₀ (nM) ± SEM			
		mMC1R	mMC3R	mMC4R	mMC5R
31		530 ± 210	25,900 ± 15,700	^a	^a
32		3030 ± 1040	^a	31,100 ± 21350	23,600 ± 1750
	α-MSH	7.2 ± 3.73	10.2 ± 2.53	19.3 ± 3.59	6.72 ± 2.01
	NDP-MSH	0.014 ± 0.002	0.09 ± 0.02	0.14 ± 0.03	0.17 ± 0.08

^a >100,000 indicates that no agonist response was observed at up to 100 mM concentrations.

conformational space with the π system of the phenyl (shown below) in lead compound **2**. In addition, pyridine and imidazole derivatives **21** and **22** with saturated C₂ chain served as flexible probes for potential basic or H-bonding sites at hMC1R near the N-terminal binding region. The N-capping groups with π -conjugated diene system (**29** and **30**) and the corresponding saturated C₄ analog **31** were chosen to explore the space beyond Ph(CH₂)₃ in **2**.



As seen in Table 1, the selectivity profile for reference compounds **1** and **2** differs from that previously reported for hMCRs.³ Tetrapeptide **1** has an EC₅₀ in the nanomolar range at mMC1R, MC4R and MC5R (MC1/3/4/5Rs ratio 1:16:0.3:0.2), while its tripeptide analog **2** retains mMC1R selectivity (MC1/3/4/5Rs ratio 1:46:16:12) albeit with 590-fold loss in potency compared to **1**. As we expected on the basis of our data for **1** and **2**^{3b} and literature data on the melanocortin core sequence⁶, removal of Trp⁹ from HfRW-NH₂ resulted in very low potency at mMC3R–MC5R. This desirable effect is most pronounced at mMC3R, where 2/3 of the synthesized tripeptides show no activity. Apparently, the binding site of mMC3R is larger than that of mMC1R, MC4R and MC5Rs and the Ph–C–C– group is too short to interact with the receptor. The elongation of the end-capping group (see the alignment above) due to aromatic substituents (**4**, **7**, **8**, **11–13** and **26**) or spacer extensions (**29–31** vs **18–19**) elicits a weak mMC3R response. This SAR is not straightforward and polar groups (**5**, **6**, **9**, **10**, **14–19**, **26** and **28**) cancel the response.

In accordance with our initial reasoning that restrictions in spacer flexibility on the tripeptide core lacking tertiary structure might produce a conformation active at MC1R, we explored an unsaturated series consisting of **3–9**, **12**, **13**, **15–18**, **20** and **23–26**. The direct unsaturated analog **26** of the parent tripeptide **2** was equipotent to **2** at mMC1R but showed some loss of selectivity (MC1/3/4/5Rs ratio 1:24:5:3). At the same time, the simple cinnamic derivative **3** was more promising—its potency at mMC1R was close to that of **2** and it showed much better selectivity (MC1/4/5Rs 1:44:25 and no activity at mMC3R). Substitution on the cinnamoyl aromatic ring revealed considerable tolerance of the mMC1R for structural changes. *meta*-Substitution (**7–9**) was

favorable with a 2–3-fold increase in potency, while the *para*-OH derivative **13** was the most potent (11×) and selective (MC1/3/4/5Rs 1:246:217:11). The *p*-OH group was essential for activity since methylation (**15**) or substitution by the isosteric and isoelectronic Cl (**12**) resulted in a substantial drop in potency (Table 1).

In an attempt to pinpoint the location of the OH binding site in mMC1R, we synthesized free rotating analogs (**14** and **10**) of semi-rigid **13** and **9**, as well as their rigid cyclic analogs (**17** and **11**). All of them were less potent than **13**, that is, the cinnamic scaffold provided an optimal positioning of the polar H-bonding group in the aromatic binding region of mMC1R.

To determine factors contributing to high potency of **13**, we did a conformational search on **2**, **13**, **11** and **17** using the Monte Carlo Multiple Minimum (MCM) mixed torsional/low-frequency sampling and the OPLS_2005 force field in water as implemented in MacroModel.⁷ The results show that although the number of conformers for **2** (108 within 3 kcal/mol, 293 within 5 kcal/mol) and **13** (55 within 3 kcal/mol, 221 within 5 kcal/mol) does not vary drastically, their 3D distribution is totally different (Fig. 1).

While **2** has no preferred conformation (Fig. 1a), all 221 conformers of **13** are very well aligned (Fig. 1b). Even though the *p*-OH does not contribute to any intramolecular bonds, the semi-rigid cinnamic tail influences the rest of otherwise flexible tripeptide core placing the polar basic Arg and His on the same side of the molecule opposite to the non-polar aromatic D-Phe and cinnamoyl. Together with the existence of **13** in multiple but similar conformations that can morph into the biologically active conformation




Figure 1. Conformations within 5 kcal/mol: (a) Ph(CH₂)₃CO-His-D-Phe-Arg-NH₂ (**2**), (b) *trans*-4-HOC₆H₄CH=CHCO-His-D-Phe-Arg-NH₂ (**13**).

upon binding, such 'pre-alignment' is beneficial for initial recognition of the ligand by the mMC1R that contains known compact acidic (Glu-94, Asp-117 and 121) and aromatic hydrophobic (Phe-175, 179, 196, and 257) binding pockets.⁸ The results of the conformational search for the cyclic analog **17** (not shown) are similar to **13**, which demonstrate that its lower potency relative to **13** is related to misplacement of HO in the active site due to an increase in girth or rigidity of the end-capping group. It is interesting to note that the drop in potency of **17** is observed on all mMCRs subtypes with the total loss of activity at mM3 and mM4Rs.

Thus, the use of semi-rigid N-capping groups with the C₂ spacer allows for a 'soft' control of the peptide conformation without restricting dihedral angles of the backbone or side chains favorable for interaction with an active site. Application of this principle to a very flexible tripeptide **2** resulted in the compound **13** that was more selective than the tridecapeptide α -MSH and only 11 times less potent at mM1R. Many of the N-capped HfR-NH₂ derivatives show low potency or are inactive at mM3 and/or MC4Rs (Table 1) and this could be relevant for future design of low molecular weight synthetic drugs acting only on targeted MCRs subtypes.¹⁰

Acknowledgments

This work was funded by Grants RO1CA114095 (Z.A.-M.), RO1DK057080 (C.H.-L.) and Skin Cancer Foundation Henry W. Menn Memorial Award (J.J.K.).

References and notes

1. *The Melanocortin Receptors*; Cone, R. D., Ed.; Humana: Totowa, 2000; Abdel-Malek, Z. *Cell. Mol. Life Sci.* **2001**, *58*, 1420; *Understanding G Protein-coupled Receptors and their Role in the CNS (The Molecular and Cellular Neurobiology Series)*; Pangalos, M., Davies, C. H., Eds.; Oxford University Press, 2002; Garcia-Borron, J. C.; Sanchez-Laorden, B. L.; Jimenez-Cervantes, C. *Pigment Cell Res.* **2005**, *18*, 393; Wikberg, J. E. S.; Mutulis, F. *Nat. Rev. Drug Disc.* **2008**, *7*, 307.
2. Todorovic, A.; Haskell-Luevano, C. *Peptides* **2005**, *26*, 2026; Hadley, M. E.; Hruby, V. J.; Jiang, J.; Sharma, S. D.; Fink, J. L.; Haskell-Luevano, C.; Bentley, D. L.; Al-Obeidi, F.; Sawyer, T. K. *Pigment Cell Res.* **2006**, *9*, 213; *Insights into Receptor Function and New Drug Development Targets (Research and Perspectives in Endocrine Interactions)*; Conn, M., Kordon, C., Christen, Y., Eds.; Springer, 2006; *Ligand Design for G Protein-coupled Receptors (Methods and Principles in Medicinal Chemistry)*; Rognan, D., Mannhold, R., Kubinyi, H., Folkers, G., Eds.; Wiley: VCH, 2006; *Current Top. Med. Chem.*, **2007**, *7*, No 11—A special issue on *Melanocortin Receptor Ligands and Their Potential Therapeutic Uses.*; Nozawa, D.; Chaki, S.; Nakazato, A. *Exp. Opin. Ther. Patents* **2008**, *18*, 403.
3. (a) Koikov, L. N.; Knittel, J. J.; Solinsky, M. G.; Cross-Doersen, D.; Ebetino, F. H. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 2647; (b) Koikov, L. N.; Knittel, J. J.; Solinsky, M. G.; Cross-Doersen, D.; Ebetino, F. H. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 3997.
4. (a) Abdel-Malek, Z. A.; Kadekaro, A. L.; Kavanagh, R. J.; Todorovic, A.; Koikov, L. N.; McNulty, J. C.; Pilgrim, J. J.; Jackson, P. J.; Millhauser, G. L.; Schwenberger, S.; Babcock, J.; Haskell-Luevano, C.; Knittel, J. J. *FASEB J.* **2006**, *20*, 1561; Abdel-Malek, Z. A.; Kavanagh, R. J.; Koikov, L. N.; Todorovic, A.; Haskell-Luevano, C.; McNulty, J. C.; Jackson, P.; Millhauser, G.; Knittel, J. J. *Pigment Cell Res.* **2004**, *17*, 449; (b) Hearing, V. J.; Rouzaud, F. *Peptides* **2005**, *26*, 1858; Abdel-Malek, Z. A.; Knittel, J. J.; Kadekaro, A. L.; Starner, R.; Swope, V. B. *Photochem. Photobiol.* **2008**, *84*, 501.
5. Haskell-Luevano, C.; Holder, J. R.; Monck, E. K.; Bauzo, R. M. *J. Med. Chem.* **2001**, *44*, 2247.
6. Hruby, V. J.; Wilkes, B. C.; Hadley, M. E.; Al-Obeidi, F.; Sawyer, T. K.; Staples, D. J.; DeVaux, A.; Dym, O.; Castrucci, A. M.; Hintz, M. F.; Riehm, J. P.; Rao, K. R. *J. Med. Chem.* **1987**, *30*, 2126; Haskell-Luevano, C.; Sawyer, T. K.; Hendrata, S.; North, C.; Panahinia, L.; Stum, M.; Staples, D. J.; Castrucci, A. M.; Hadley, M. E.; Hruby, V. J. *Peptides* **1996**, *17*, 995; Sahm, U. G.; Oliver, G. W. J.; Branco, S. K.; Moss, S. H.; Pouton, C. W. *Peptides* **1994**, *15*, 1297; Sahm, U. G.; Quarawi, M. A.; Oliver, G. W. J.; Ahmed, A. R. H.; Moss, S. H.; Pouton, C. W. *FEBS Lett.* **1994**, *350*, 29; Bednarek, M. A.; Silva, M. V.; Arison, B.; MacNeil, T.; Kalyani, R. N.; Huang, R.-R. C.; Weinberg, D. H. *Peptides* **1999**, *20*, 401; Bednarek, M. A.; MacNeil, T.; Kalyani, R. N.; Tang, R.; Van der Ploeg, L. H. T.; Weinberg, D. H. *Biochem. Biophys. Res. Commun.* **1999**, *261*, 209; Holder, J. R.; Xiang, Z.; Bauzo, R.; Haskell-Luevano, C. *J. Med. Chem.* **2002**, *45*, 5736; Bednarek, M. A.; MacNeil, T.; Tang, R.; Tung, M. F.; Cabello, M. A.; Maroto, M.; Teran, A. *Biopolymers* **2007**, *89*, 401.
7. Schrodinger Suite 2008, Schrodinger LLC, New York, NY, **2008**.
8. Haskell-Luevano, C.; Sawyer, T. K.; Trumpp-Kallmayer, S.; Bikker, J. A.; Humblet, C.; Gantz, I.; Hruby, V. J. *Drug Des. Discovery* **1996**, *14*, 197; Yang, Y.; Dickinson, C.; Haskell-Luevano, C.; Gantz, I. *J. Biol. Chem.* **1997**, *272*, 23000; Haskell-Luevano, C.; Rosenquist, A.; Souers, A.; Khong, K. C.; Ellman, J. A.; Cone, R. C. *J. Med. Chem.* **1999**, *42*, 4380; Holder, J. R.; Haskell-Luevano, C. *Med. Res. Rev.* **2004**, *24*, 325; Hogan, K.; Peluso, S.; Gould, S.; Parsons, I.; Ryab, D.; Wu, L.; Visiers, I. *J. Med. Chem.* **2006**, *49*, 911.
9. Koikov, L.; Ruwe, A. R.; Abdel-Malek, Z.; Haskell-Luevano, C.; Dirain, M. L.; Portillo, F.; Xiang, Z.; Wortman, M.; Knittel, J. J. *Pept. Sci.* **2009**, *92*, 362; Abstract P263, American Peptide Symposium 2009, Bloomington, IN.; Jois, S. D. S.; Koikov, L.; Abdel-Malek, Z.; Kavanagh, R.; Wortman, M.; Knittel, J. J. *ibid.*, p. 361, Abstract P259.
10. Nickolls, S. A.; Cismowski, M. I.; Wang, X.; Wolf, M.; Conlon, P. J.; Maki, R. A. *J. Pharmacol. Exp. Ther.* **2003**, *304*, 1217; Sun, H.; Fry, D. *Curr. Top. Med. Chem.* **2007**, *7*, 1042.
11. Compounds **1–32** (purity >95%) were obtained, analyzed and assayed as previously described.^{3,5} The EC₅₀ values for compounds **1–32** (all of them are full agonists) in Table 1 are an average of at least three separate experiments with the associated standard error of the mean.